These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 33031517

  • 1. Functional Evaluation and Genetic Evolution of Human T-Cell Responses After Vaccination With a Conditionally Replication-Defective Cytomegalovirus Vaccine.
    Cox KS, Zhang L, Freed DC, Tang A, Zhang S, Zhou Y, Wang IM, Rupp RE, Adler SP, Musey LK, Wang D, Vora KA, Fu TM.
    J Infect Dis; 2021 Jun 04; 223(11):2001-2012. PubMed ID: 33031517
    [Abstract] [Full Text] [Related]

  • 2. A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    Liu Y, Freed DC, Li L, Tang A, Li F, Murray EM, Adler SP, McVoy MA, Rupp RE, Barrett D, Ye X, Zhang N, Beck K, Culp T, Das R, Song L, Vora K, Zhu H, Wang D, Espeseth AS, An Z, Musey L, Fu TM.
    J Virol; 2019 Dec 01; 93(23):. PubMed ID: 31511385
    [Abstract] [Full Text] [Related]

  • 3. Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.
    Adler SP, Lewis N, Conlon A, Christiansen MP, Al-Ibrahim M, Rupp R, Fu TM, Bautista O, Tang H, Wang D, Fisher A, Culp T, Das R, Beck K, Tamms G, Musey L, V160-001 Study Group.
    J Infect Dis; 2019 Jul 02; 220(3):411-419. PubMed ID: 31535143
    [Abstract] [Full Text] [Related]

  • 4. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients.
    Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Adler SP.
    J Clin Virol; 2006 Mar 02; 35(3):332-7. PubMed ID: 16387547
    [Abstract] [Full Text] [Related]

  • 5. Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.
    Wu K, Hou YJ, Makrinos D, Liu R, Zhu A, Koch M, Yu W-H, Paila YD, Chandramouli S, Panther L, Henry C, DiPiazza A, Carfi A.
    J Virol; 2024 Apr 16; 98(4):e0160323. PubMed ID: 38526054
    [Abstract] [Full Text] [Related]

  • 6. Delineating the role of CD4+ T cells in the activation of human cytomegalovirus-specific immune responses following immunization with Ad-gBCMVpoly vaccine: implications for vaccination of immunocompromised individuals.
    Zhong J, Khanna R.
    J Gen Virol; 2010 Dec 16; 91(Pt 12):2994-3001. PubMed ID: 20810748
    [Abstract] [Full Text] [Related]

  • 7. Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine.
    Ye X, Shih DJH, Ku Z, Hong J, Barrett DF, Rupp RE, Zhang N, Fu TM, Zheng WJ, An Z.
    NPJ Vaccines; 2024 Apr 01; 9(1):70. PubMed ID: 38561339
    [Abstract] [Full Text] [Related]

  • 8. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR, Berka U, Watson E, Aistleithner M, Kiefmann B, Mangeat B, Swanson EC, Gillis PA, Hernandez-Alvarado N, Fernández-Alarcón C, Zabeli JC, Pinschewer DD, Lilja AE, Schwendinger M, Guirakhoo F, Monath TP, Orlinger KK.
    Clin Vaccine Immunol; 2017 Jan 01; 24(1):. PubMed ID: 27795301
    [Abstract] [Full Text] [Related]

  • 9. Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates.
    Li H, Monslow MA, Freed DC, Chang D, Li F, Gindy M, Wang D, Vora K, Espeseth AS, Petrovsky N, Fu TM.
    Vaccine; 2021 Dec 17; 39(51):7446-7456. PubMed ID: 34852943
    [Abstract] [Full Text] [Related]

  • 10. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.
    Cardin RD, Bravo FJ, Pullum DA, Orlinger K, Watson EM, Aspoeck A, Fuhrmann G, Guirakhoo F, Monath T, Bernstein DI.
    Vaccine; 2016 Apr 12; 34(17):1993-9. PubMed ID: 26973071
    [Abstract] [Full Text] [Related]

  • 11. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity.
    John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA, Ciaramella G.
    Vaccine; 2018 Mar 14; 36(12):1689-1699. PubMed ID: 29456015
    [Abstract] [Full Text] [Related]

  • 12. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.
    Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P, Olmsted RA, Hoeper A, Morris J, Negri S, Maughan MF, Chulay JD.
    Vaccine; 2009 Dec 11; 28(2):484-93. PubMed ID: 19857446
    [Abstract] [Full Text] [Related]

  • 13. Memory CD8 T Cells Generated by Cytomegalovirus Vaccine Vector Expressing NKG2D Ligand Have Effector-Like Phenotype and Distinct Functional Features.
    Šustić M, Cokarić Brdovčak M, Lisnić B, Materljan J, Juranić Lisnić V, Rožmanić C, Indenbirken D, Hiršl L, Busch DH, Brizić I, Krmpotić A, Jonjić S.
    Front Immunol; 2021 Dec 11; 12():681380. PubMed ID: 34168650
    [Abstract] [Full Text] [Related]

  • 14. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
    Wang Z, La Rosa C, Lacey SF, Maas R, Mekhoubad S, Britt WJ, Diamond DJ.
    J Clin Virol; 2006 Mar 11; 35(3):324-31. PubMed ID: 16388983
    [Abstract] [Full Text] [Related]

  • 15. Development of a cytomegalovirus vaccine: lessons from recent clinical trials.
    Gonczol E, Plotkin S.
    Expert Opin Biol Ther; 2001 May 11; 1(3):401-12. PubMed ID: 11727514
    [Abstract] [Full Text] [Related]

  • 16. Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV.
    Bunse L, Sommerer C, Tan CL, Korell F, Schmitt A, Hückelhoven-Krauss A, Neuber B, Mertens T, Platten M, Green EW, Zeier M, Schmitt M.
    Int J Mol Sci; 2022 Jan 18; 23(3):. PubMed ID: 35162953
    [Abstract] [Full Text] [Related]

  • 17. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.
    La Rosa C, Longmate J, Lacey SF, Kaltcheva T, Sharan R, Marsano D, Kwon P, Drake J, Williams B, Denison S, Broyer S, Couture L, Nakamura R, Dadwal S, Kelsey MI, Krieg AM, Diamond DJ, Zaia JA.
    J Infect Dis; 2012 Apr 15; 205(8):1294-304. PubMed ID: 22402037
    [Abstract] [Full Text] [Related]

  • 18. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
    Lilja AE, Mason PW.
    Vaccine; 2012 Nov 19; 30(49):6980-90. PubMed ID: 23041121
    [Abstract] [Full Text] [Related]

  • 19. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases.
    Selinsky C, Luke C, Wloch M, Geall A, Hermanson G, Kaslow D, Evans T.
    Hum Vaccin; 2005 Nov 19; 1(1):16-23. PubMed ID: 17038834
    [Abstract] [Full Text] [Related]

  • 20. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy.
    Zandvliet ML, van Liempt E, Jedema I, Veltrop-Duits LA, Willemze R, Guchelaar HJ, Falkenburg JH, Meij P.
    Cytotherapy; 2010 Nov 19; 12(7):933-44. PubMed ID: 20078388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.